ReviewCancer immunology, immunotherapy : CII2004
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Review in Cancer immunology, immunotherapy : CII, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 181 citations in OpenAlex.
- Trial
- Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.Cancer immunology, immunotherapy : CII · 2006Trial
- Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.International journal of hematology · 2024Review
- Tumor vaccines: Toward multidimensional anti-tumor therapies.Human vaccines & immunotherapeutics · 2023Review
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Nature communications · 2023Article
- Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.Research square · 2023Article
- Natural killer cells and acute myeloid leukemia: promises and challenges.Cancer immunology, immunotherapy : CII · 2022Review
- Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond.Frontiers in immunology · 2022Review
- Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State.Current oncology (Toronto, Ont.) · 2021Observational
- Heterogeneity of Glucose Transport in Lung Cancer.Biomolecules · 2020Review
- Cancer immunotherapy using the Fusion gene of Sendai virus.Cancer gene therapy · 2020Article
- Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.Transfusion · 2019Article
- Dominant role of the α-chain in rejection of tumor cells bearing a specific alloantigen in TCRα transgenic mice and inOncotarget · 2019Article
- TGF-BETA IN THE NATURAL HISTORY OF PROSTATE CANCER.Acta clinica Croatica · 2019Review
- Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.Human vaccines & immunotherapeutics · 2019Review
- Article
- A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2017Article
- Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.Journal of biomedical science · 2017Review
- Review
- Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by the immune system under optimum conditions for activating adaptive and nonadaptive antitumor immune responses. Despite this capability, a large number of tumors continue to grow and evade recognition and/or destruction by the immune system. The limited success in current immunotherapeutic strategies may be due to a variety of reasons: failure of effector cells to compete with the growing tumor burden, production of humoral factors by tumors that locally block cytotoxicity, antigen/MHC loss, T-cell dysfunction, production of suppressor T cells-to name but a few causes for therapeutic ineffectiveness for the particular malignancy being treated. To optimize immunotherapy strategies, correction of immune-activating signals, eradication of inhibitory factors, and the evasion from newly developed immunoresistant tumor phenotypes need to be simultaneously considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.